BiotechTube

ZYNRELEF 200Mg-6Mg Extended-Release Solution

ApprovedUNKNOWN
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Post Operative Pain, Acute

Conditions

Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain

Trial Timeline

May 9, 2023 → Oct 9, 2024

NCT ID
NCT05863221

About ZYNRELEF 200Mg-6Mg Extended-Release Solution

ZYNRELEF 200Mg-6Mg Extended-Release Solution is a approved stage product being developed by Heron Therapeutics for Post Operative Pain, Acute. The current trial status is unknown. This product is registered under clinical trial identifier NCT05863221. Target conditions include Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05863221ApprovedUNKNOWN

Competing Products

20 competing products in Post Operative Pain, Acute

See all competitors
ProductCompanyStageHype Score
PRF110- oily solution (Ropivacaine)PainReformPhase 2
44
PRF110PainReformPhase 2
44
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
raloxifene + PlaceboEli LillyApproved
85
MBX 1416 (INN imapextide)MBX BiosciencesPhase 2
47
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)MBX BiosciencesPhase 1
28
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
LetrozoleChugai PharmaceuticalPhase 2
52
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
LetrozoleChugai PharmaceuticalPhase 2
52
LetrozoleChugai PharmaceuticalPhase 2
52
Placebo + DS-5565Daiichi SankyoPre-clinical
23
YM177 + etodolac + PlaceboAstellas PharmaPhase 3
77
QUTENZAAstellas PharmaApproved
85
QutenzaAstellas PharmaPre-clinical
23
CelecoxibAstellas PharmaPre-clinical
23
ASP8477 + PlaceboAstellas PharmaPhase 2
52

Other Products from Heron Therapeutics

SUSTOLApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine HClApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionApproved
77